Fig. 4

Comprehensive analysis of the RNA methylation risk score in glioma. GSEA between the low- and high-risk groups, including the top 10 GO terms (A) and KEGG pathways (B). C Differences in the abundance of 24 immune cells between the low- and high-risk groups (Kruskal‒Wallis test). D Pearson correlation analysis between RNA methylation-related lncRNAs and 24 immune cells in the TCGA database. E Differences in responses to ICI therapy (anti-PD-1 and CTLA-4 therapies) between the low- and high-risk groups using the TIDE algorithm. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. F Heatmap of ICI expression for PD-1 and CTLA4 in the low- and high-risk score groups through SubMap. G Differences in the IC50 values of three chemotherapeutic drugs for glioma between the low- and high-risk groups. GSEA Gene Set Enrichment Analysis, GO Gene Ontology, KEGG Kyoto Encyclopedia of Genes and Genomes, ICI immune checkpoint inhibitor, IC50 half-maximal inhibitory concentration